Verizon to cut 15,000 jobs amid growing competition pressures - WSJ
Investing.com - Deutsche Bank upgraded Swedish Orphan Bio (SOBI:SS) (OTC:SWTUY) stock rating from Hold to Buy and raised its price target to SEK370.00 from SEK285.00.
The upgrade follows Swedish Orphan Bio’s Q3 results, which were released earlier than scheduled on October 20 due to the company beating expectations and raising its fiscal year 2025 guidance.
Deutsche Bank noted that the Q3 margin raise largely addressed previous concerns about operating expense management heading into fiscal year 2026, while recent product developments have improved the company’s mid-term outlook.
Key upcoming catalysts include an Aspaveli C3G European Medicines Agency decision expected in Q4, an FDA decision on NASP gout treatment in June, and the potential launch of olezarsen for MCS likely in 2027.
Deutsche Bank also highlighted that recent venture capital rounds for gout startups Arthrosi and Crystalys suggest "informed optimism" about the market opportunity, despite the bank’s own cautious stance on this segment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.